The Snail-p53 binding as the new therapeutic target for K-Ras-mutated cancers including pancreatic, lung, and colon cancers.

K-ras, EGFR, and BRAF mutations are disproportionately seen in adenocarcinomas of lung with a dominant micropapillary growth pattern compared with conventional adenocarcinoma in our institutional experience.

mutations may predict the biological nature of pulmonary adenocarcinomas and facilitate new therapies.

An association exists between TRAIL resistance to apoptosis in human pancreatic and lung cancer cell lines and G12D K-ras(12) mutation.

The frequency of EGFR mutation in Chinese non-small cell lung cancer patients is higher than that in Westerners, but the frequency of K-ras mutation is quite opposite.

EGFR and K-ras mutations frequently occur randomly in multifocal lung adenocarcinomas

Cell-type specific tumorigenesis with Ras oncogenes in human lung epithelial cells.

Organ susceptibility of rasH2(+/-) mice is inherited from their strains of origin,the rasH2 and BALB/c lines are more sensitive to the induction of pulmonary carcinogesis.